Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 6:13:905947.
doi: 10.3389/fphar.2022.905947. eCollection 2022.

Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer

Dehua Liao  1 , Lun Yu  2 , Dangang Shangguan  1 , Yongchang Zhang  3 , Bowen Xiao  1 , Ni Liu  1 , Nong Yang  3
Affiliations
Review

Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer

Dehua Liao et al. Front Pharmacol. .

Abstract

Lung cancer is the leading cause of cancer-related deaths with high morbidity and mortality. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of all cases. Fortunately, the development of molecular oncology provides a promising and effective therapeutic strategy for lung cancers, including specific gene mutations/translocations and immune checkpoints, with epidermal growth factor receptor (EGFR) common mutations first and anaplastic lymphoma kinase (ALK) translocations later as the targeted therapy and immune checkpoint inhibitors (ICIs) as immunotherapy. This review summarized the recent therapy advancements of TKIs and ICIs in NSCLC and focused on the clinical effect of combination or sequential treatment so as to provide the effective advice for the treatment of NSCLC.

Keywords: ICIs; NSCLC; TKIs; combination treatment; sequential treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Ahn M.-J., Yang J., Yu H., Saka H., Ramalingam S., Goto K., et al. (2016). 136O: Osimertinib Combined with Durvalumab in EGFR-Mutant Non-small Cell Lung Cancer: Results from the TATTON Phase Ib Trial. J. Thorac. Oncol. 11 (4), S115. 10.1016/s1556-0864(16)30246-5 - DOI
    1. Akbay E. A., Koyama S., Carretero J., Altabef A., Tchaicha J. H., Christensen C. L., et al. (2013). Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors. Cancer Discov. 3 (12), 1355–1363. 10.1158/2159-8290.CD-13-0310 - DOI - PMC - PubMed
    1. Alice T., Shaw S.-H. L. (2018). Avelumab (Anti– PD-L1) in Combination with Crizotinib or Lorlatinib in Patients with Previously Treated Advanced NSCLC Phase 1b Results from JAVELIN Lung 101. Clin. Trial 18 (5), 599–610.
    1. Azuma K., Ota K., Kawahara A., Hattori S., Iwama E., Harada T., et al. (2014). Association of PD-L1 Overexpression with Activating EGFR Mutations in Surgically Resected Nonsmall-Cell Lung Cancer. Ann. Oncol. 25 (10), 1935–1940. 10.1093/annonc/mdu242 - DOI - PubMed
    1. Azzoli C. G., Baker S., Jr, Temin S., Pao W., Aliff T., Brahmer J., et al. (2009). American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-small-cell Lung Cancer. J. Clin. Oncol. 27 (36), 6251–6266. 10.1200/JCO.2009.23.5622 - DOI - PMC - PubMed